A placebo-controlled study of three agomelatine dose regimens (10mg, 25mg, 25-50mg) in patients with major depressive disorder

European Neuropsychopharmacology

Volumn 24, Issue 4, 2014, Pages 553-563

  Kennedy, Sidney H ^a   Avedisova, Alla ^b   Giménez Montesinos, Natalia ^c   Belaïdi, Carole ^c   Christian de, Bodinat ^c   Corral, Ricardo Marcelo ^d   Caches, Mariano Alvarez ^d   Lamaison, Héctor Fabián ^d   Gargoloff, Pedro Rafael ^d   Lupo, Christian ^d   Finkelsztein, Carlos ^d   Berardo, Germán Mauricio ^d   Mosca, Daniel ^d   Serfaty, Edith Mirta ^d   Kuper, Enrique ^d   Milanova, Vihra ^d   Onchev, Georgi ^d   Gaidarova, Radka ^d   Popov, Georgi ^d   Sayan, Loris ^d   Georgiev, Svetlozar ^d   Akabaliev, Valentin ^d   MatevA, Temenuzhka ^d   Ahokas, Antti ^d   Penttinen, Jukka ^d   Pirilä, Marja ^d   Grigorieva, Elena ^d   Ivanov, Mikhail ^d   Kasimova, Lala ^d   Mosolov, Sergei ^d   Neznanov, Nikolay ^d   Smulevich, Anatoly ^d   Vasilyeva, Anna ^d   Shiryaev, Oleg ^d   Tochilov, Vladimir ^d   Vavrusova, Livia ^d   Garaj, Vladimir ^d   Kuriackova, Nada ^d   Janikova, Zuzana ^d   Biackova, Monika ^d   Chaban, Oleg ^d   Abramov, Volodymyr ^d   Filts, Olexandr ^d   Demchenko, Vladyslav ^d   Maruta, Nataliya ^d   Mykhnyak, Sergiy ^d   Napryeyenko, Oleksandr ^d   Pidkorytov, Valeriy ^d   Pishel, Vitaliy ^d   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b Serbsky State Scientific Center of Social and Forensic Psychiatry   (Russian Federation)

^c IRIS Institut de Recherches Internationales Servier   (France)

^d NONE

Author keywords

Agomelatine; Depression; Dose regimen; Placebo

Indexed keywords

AGOMELATINE; PLACEBO; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; SEROTONIN 2 ANTAGONIST; SEROTONIN 2C RECEPTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SOCIAL INTERACTION; SOMNOLENCE; TREATMENT DURATION; XEROSTOMIA; YOUNG ADULT; ADOLESCENT; AGONISTS; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT DROPOUT; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHAVIOR DISORDER; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; HAMILTON DEPRESSION RATING SCALE; INSOMNIA; LOW DRUG DOSE; RESTLESSNESS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84895892267     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.01.006     Document Type: Article

References (26)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC. 4th ed.
2. Beasley C.M., Bosomworth J.C., Wernicke J.F. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol. Bull. 1990, 26:18-24.
3. Bech P., Tanghoj P., Andersen H.F., Overo K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl.) 2002, 163:20-25.
4. Berney P. Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialog. Clin. Neurosci. 2005, 7:249-262.
5. Burke W.J., Gergel I., Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J. Clin. Psychiatry 2002, 63:331-336.
6. de Bodinat C., Guardiola-Lemaitre B., Mocaer E., Renard P., Munoz C., Millan M.J. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat. Rev. Drug Discov. 2010, 9:628-642.
7. Dunner D.L., Dunbar G.C. Optimal dose regimen for paroxetine. J. Clin. Psychiatry 1992, 53(Suppl.):S21-S26.
8. Fabre L.F., Abuzzahab F.S., Amin M., Claghorn J.L., Mendels J., Petrie W.M., Dube S., Small J.G. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol. Psychiatry 1995, 38:592-602.
9. Fabre L.F., Putman H.P. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J. Clin. Psychiatry 1987, 48:406-408.
10. Fredman S.J., Fava M., Kienke A.S., White C.N., Nierenberg A.A., Rosenbaum J.F. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J. Clin. Psychiatry 2000, 61(6):403-408.
11. Goodwin G.M. Clinical studies on the efficacy of agomelatine on depressive symptoms. CNS Drugs 2009, 23(Suppl 2):S35-S39.
12. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare Publication ADM 76-338 1976, 217-222. National Institute of Mental Health, Rockville, MD.
13. Heun R., Ahokas A., Boyer P., Giménez-Montesinos N., Pontes-Soares F., Olivier V. The efficacy of agomelatine in elderly patients with major recurrent depressive disorder: a placebo controlled study. J. Clin. Psychiatry 2014.
14. Hickie I.B., Rogers N.L. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011, 378:621-631.
15. Kennedy S.H., Rizvi S.J. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010, 24:479-499.
16. Khan A., Upton G.V., Rudolph R.L., Entsuah R., Leventer S.M. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine investigator study group. J. Clin. Psychopharmacol. 1998, 18:19-25.
17. Loo H., Hale A., D'haenen H Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-ht2c antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. 2002, 17:239-247.
18. Mallinckrodt C.H., Prakash A., Andorn A.C., Watkin J.G., Wohlreich M.M. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J. Psychiatr. Res. 2006, 40:337-348.
19. Mendels J., Johnston R., Mattes J., Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol. Bull. 1993, 29:169-174.
20. Montgomery S.A., Pedersen V., Tanghoj P., Rasmussen C., Rioux P. The optimal dosing regimen for citalopram-a meta-analysis of nine placebo-controlled studies. Int. Clin. Psychopharmacol. 1994, 9(Suppl. 1):S35-S40.
21. Montgomery S.A., Rasmussen J.G., Tanghoj P. A 24-week study of 20mg citalopram, 40mg citalopram, and placebo in the prevention of relapse of major depression. Int. Clin. Psychopharmacol. 1993, 8:181-188.
22. Rudolph R.L., Fabre L.F., Feighner J.P., Rickels K., Entsuah R., Derivan A.T. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J. Clin. Psychiatry 1998, 59:116-122.
23. Ruhe H.G., Booij J., Weert H.C., Reitsma J.B., Franssen E.J., Michel M.C., Schene A.H. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 2009, 34:999-1010.
24. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):S22-S33.
25. Wernicke J.F., Dunlop S.R., Dornseif B.E., Bosomworth J.C., Humbert M. Low-dose fluoxetine therapy for depression. Psychopharmacol. Bull. 1988, 24:183-188.
26. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67:361-370.